Jack A. Khattar - Sep 14, 2022 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role
President, CEO, Director
Signature
/s/ Timothy C. Dec, as attorney-in-fact
Stock symbol
SUPN
Transactions as of
Sep 14, 2022
Transactions value $
-$46,575
Form type
4
Date filed
9/15/2022, 05:15 PM
Previous filing
Aug 18, 2022
Next filing
Nov 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SUPN Common Stock Options Exercise $0 +5.9K +0.76% $0.00 781K Sep 14, 2022 Direct
transaction SUPN Common Stock Options Exercise -$46.6K -1.38K -0.18% $33.75 780K Sep 14, 2022 Direct F1, F2
holding SUPN Common Stock 1.05M Sep 14, 2022 By the KBT Trust
holding SUPN Common Stock 4K Sep 14, 2022 By son F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SUPN Stock Appreciation Right Options Exercise $0 -5.9K -100% $0.00* 0 Sep 14, 2022 Common Stock 5.9K $7.90 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to the terms of the stock appreciation right ("SAR"), upon settlement of the SAR the Reporting Person is entitled to receive shares of common stock in an amount equal to the excess of the fair market value of the common stock on the date of exercise over the base value per share of common stock established at the time the SAR was granted. This transaction reports the number of shares of common stock equal to the difference between the number of shares underlying the exercised SAR and the number of shares issued to the Reporting Person.
F2 The price reported in Column 4 is the closing price of the common stock on August 29, 2022, the date of the SAR's exercise, as reported by NASDAQ Stock Market, LLC.
F3 The Reporting Person disclaims beneficial ownership of the shares held by his son, who shares the Reporting Person's household, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose.
F4 The SAR vested in four equal annual installments beginning on February 5, 2014.